NCT02867735View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 21, 2016

Primary Completion Date

February 15, 2018

Study Completion Date

February 15, 2018

Conditions
Macular EdemaDiabetic Macular EdemaNeovascular Age-related Macular DegenerationRetinal Vein Occlusions
Interventions
DRUG

LKA651

Interventional

OTHER

Sham Comparator

Trial Locations (6)

30909

Novartis Investigative Site, Augusta

33143

Novartis Investigative Site, Miami

33880

Novartis Investigative Site, Winter Haven

33901

Novartis Investigative Site, Fort Myers

91105-3153

Novartis Investigative Site, Pasadena

00612

Novartis Investigative Site, Arecibo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY